JOSEPH VISCEGLIA: Open Payments
NPI 1477177525 · LYKENS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 52 payments from 16 companies in 2025. Trend: 2023 $1,173 · 2024 $1,067 · 2025 $936
Food & beverage: $936
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $176 |
| ABBVIE INC. | 8 | $152 |
| Novo Nordisk Inc | 9 | $140 |
| GlaxoSmithKline, LLC. | 4 | $85 |
| Dexcom, Inc. | 3 | $68 |
| CeQur Corporation | 1 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
Products named: SHINGRIX, QULIPTA, Wegovy, NURTEC ODT, Dexcom G6 Transmitter, PREVNAR 20, ELIQUIS, CeQur Simplicity.
Industry payments across PA — which companies pay providers there.
